{"id":32156,"date":"2025-04-21T17:01:10","date_gmt":"2025-04-21T09:01:10","guid":{"rendered":"https:\/\/flcube.com\/?p=32156"},"modified":"2025-04-21T17:01:11","modified_gmt":"2025-04-21T09:01:11","slug":"akesos-ebdarokimab-receives-nmpa-approval-for-moderate-to-severe-plaque-psoriasis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32156","title":{"rendered":"Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis"},"content":{"rendered":"\n

China’s Akeso Biopharma (HKG: 9926<\/a>) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.<\/p>\n\n\n\n

Mechanism of Action<\/strong>
Ebdarokimab works by binding to the p40 subunit of IL-12 and IL-23, blocking their interaction with cell surface receptors. This action reduces the release of cytokines like interferon-\u03b3, TNF-\u03b1, and IL-17 from T cells, thereby modulating the immune response that drives psoriasis.<\/p>\n\n\n\n

Clinical Profile and Patient Benefits<\/strong>
As the first and only domestically developed IL-12\/IL-23 mAb in China, ebdarokimab has demonstrated significant clinical efficacy and excellent safety. Administered only four times a year, the drug improves medication compliance and leads to long-term stable improvements in treatment efficacy and quality of life for patients.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China’s Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National…<\/p>\n","protected":false},"author":1,"featured_media":32157,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[360,65,850,15],"class_list":["post-32156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-akeso-biopharma","tag-auto-immune","tag-hkg-9926","tag-product-approvals"],"yoast_head":"\nAkeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32156\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis\" \/>\n<meta property=\"og:description\" content=\"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32156\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-21T09:01:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-21T09:01:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis\",\"datePublished\":\"2025-04-21T09:01:10+00:00\",\"dateModified\":\"2025-04-21T09:01:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2117.webp\",\"keywords\":[\"Akeso Biopharma\",\"Auto-immune\",\"HKG: 9926\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32156#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32156\",\"name\":\"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2117.webp\",\"datePublished\":\"2025-04-21T09:01:10+00:00\",\"dateModified\":\"2025-04-21T09:01:11+00:00\",\"description\":\"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32156\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2117.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2117.webp\",\"width\":1080,\"height\":608,\"caption\":\"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32156#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry","description":"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32156","og_locale":"en_US","og_type":"article","og_title":"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis","og_description":"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.","og_url":"https:\/\/flcube.com\/?p=32156","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-21T09:01:10+00:00","article_modified_time":"2025-04-21T09:01:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32156#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32156"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis","datePublished":"2025-04-21T09:01:10+00:00","dateModified":"2025-04-21T09:01:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32156"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32156#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","keywords":["Akeso Biopharma","Auto-immune","HKG: 9926","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32156#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32156","url":"https:\/\/flcube.com\/?p=32156","name":"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32156#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32156#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","datePublished":"2025-04-21T09:01:10+00:00","dateModified":"2025-04-21T09:01:11+00:00","description":"China's Akeso Biopharma (HKG: 9926) announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its monoclonal antibody (mAb) ebdarokimab, targeting IL-12 and IL-23. The approval allows the drug to be used in patients with moderate to severe plaque psoriasis who are unresponsive, contraindicated, or intolerant to other systemic treatments such as cyclosporine, methotrexate (MTX), or PUVA.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32156#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32156"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32156#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","width":1080,"height":608,"caption":"Akeso's Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32156#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Akeso’s Ebdarokimab Receives NMPA Approval for Moderate to Severe Plaque Psoriasis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2117.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32156"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32156\/revisions"}],"predecessor-version":[{"id":32158,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32156\/revisions\/32158"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32157"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}